Key Highlights

● Third-quarter Revenue rose 2% to $1.65 billion.

● The net loss narrowed 95% to $1 million, with adjusted EBITDA at $31 million.

● Dividends totaled $69 million in the first nine months of 2026.

● Adjusted cash was $119 million against $420 million of Credit Facility borrowings.

Insperity, Inc. (NYSE:NSP) has drawn attention for its Margin recovery, but its Balance Sheet tells a parallel story. Through the first nine months of 2026, the professional employer organization paid out more in dividends than it earned in net income, while carrying borrowings on its credit facility. For a company whose Earnings are recovering from a difficult period of elevated benefits costs, the question of how Capital returns line up with cash generation may become more prominent as investors look toward 2027.

Latest Company Context

Insperity reported third-quarter results on Oct. 29. Revenue rose 2% to $1.65 billion, the net loss narrowed 95% to $1 million and adjusted EBITDA rose 210% to $31 million. Adjusted EPS was $0.22. Average paid worksite employees fell 2% to 307,265, while Gross Profit per worksite employee rose 8% to $225. Year to date, Net Income rose 38% to $36 million and adjusted EBITDA increased 18% to $170 million. The company reported cash and equivalents of $599 million, but adjusted cash, which excludes amounts held for client obligations, was $119 million at Sept. 30, against $420 million of credit facility borrowings. Dividends totaled $69 million in the first nine months, and the company repurchased about 302,000 shares for $10 million over the same period.

Key Business and index Drivers

The core balance sheet issue is the gap between dividends and earnings. Year-to-date dividends of $69 million compare with net income of $36 million, meaning payouts have been funded partly from other sources, including existing Liquidity and borrowing capacity. The modest pace of buybacks, just $6 million in the third quarter, suggests management is already conserving cash. Earnings improvement is the main lever that could close the gap. Chief Executive Paul Sarvadi cited continued progress on margin recovery, and Chief Financial Officer James Allison described year-over-year growth in gross profit per worksite employee as a key milestone.

Benefits cost per covered employee rose 4% in the third quarter and 5% year to date, so pricing discipline relative to healthcare cost trends may determine how quickly profitability, and therefore cash flow, recovers. Worksite employee growth would add a further boost. Management has also pointed to AI as a potential source of Demand for its HR services among small and midsize businesses, which, if realized, could support enrollment and spread fixed costs across a larger client base.

What Investors Should Watch

Insperity's fourth-quarter guidance calls for adjusted EBITDA of $24 million to $44 million and adjusted EPS of $0.07 to $0.42, a wide range that may reflect uncertainty around year-end benefits costs. Full-year 2026 guidance is adjusted EBITDA of $194 million to $214 million and net income of $32 million to $45 million. Investors may watch the next quarterly Dividend declaration for any change in the payout, and the year-end balance sheet for movement in adjusted cash and credit facility borrowings. The fourth-quarter report, which Insperity has typically released in February, had no confirmed date. Any 2027 outlook, particularly on worksite employee growth and benefits cost assumptions, could indicate whether earnings are expected to cover the dividend more comfortably next year.

Margin Recovery Meets Heavy Payouts

Insperity's margin recovery is visible in its quarterly numbers, but the balance sheet shows the strain of maintaining Shareholder payouts through a period of weak earnings. The company retains liquidity and has trimmed buybacks, giving it flexibility. How quickly earnings and Cash Flow rebuild relative to the dividend may be one of the more important variables for investors following the stock into 2027. The fourth-quarter results and the year-end balance sheet could provide the clearest read yet on whether that gap is narrowing or persisting.